Nepafenac Once Daily for Macular Edema - Study 2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 819 participants.
Also called NCT01872611
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 819 participants
- Sponsor
- Alcon Research
- Registry
-
NCT01872611 -
2013-001874-12
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01872611. Randomized; double masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2015-05 (actual). Results posted on 2016-08-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Nepafenac Once Daily for Macular Edema - Study 2
- Condition
- Non-Proliferative Diabetic Retinopathy
- Condition
- Cataract
- Intervention (Drug)
- Nepafenac Ophthalmic Suspension, 0.3%
- Intervention (Other)
- Vehicle
- Intervention (Drug)
- Prednisolone acetate
- Lead sponsor
- Alcon Research
Record details
- Record id
cardio:ct-nct01872611- Content hash
477227eb6de547bda9093d8e6ae0d2d072b102e8dc87b56eb6c2a6254807bde0